LCFEX-Mont Tablet is a combination pharmaceutical formulation containing Montelukast 10 mg and Fexofenadine 120 mg, designed for the management of allergic conditions. Montelukast, a leukotriene receptor antagonist, works by inhibiting the action of leukotrienes, inflammatory mediators involved in bronchoconstriction, mucus secretion, and airway edema, thereby providing relief from symptoms associated with asthma and allergic rhinitis. Fexofenadine, a second-generation antihistamine, selectively blocks peripheral H1 receptors, reducing histamine-induced symptoms such as sneezing, nasal congestion, itching, and urticaria without causing significant sedation. The synergistic action of these agents in LCFEX-Mont Tablet offers effective control of allergic manifestations, including seasonal allergic rhinitis, chronic idiopathic urticaria, and asthma-related symptoms. This combination is particularly beneficial for patients requiring comprehensive symptom management with improved compliance due to reduced pill burden. LCFEX-Mont Tablet should be administered as prescribed by a healthcare professional, typically once daily, and is generally well tolerated. Caution is advised in patients with hepatic impairment or hypersensitivity to either component. This medication is not intended for acute asthma attacks and should be used under medical supervision to optimize therapeutic outcomes and minimize adverse effects.